New incretin-based therapies like semaglutide and tirzepatide show significant weight loss and improved obesity-related outcomes in adults.
Semaglutide leads to substantial weight reduction, with more patients achieving at least 15% and 20% weight loss compared to control groups.
Tirzepatide results in nearly 12% body weight reduction and increases the proportion of patients achieving clinically meaningful weight loss.
GLP-1 receptor agonists may improve conditions like obstructive sleep apnea and metabolic dysfunction-associated liver disease.
The Obesity Society recommends semaglutide and tirzepatide for adults with obesity and suggests continued therapy during weight maintenance.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
